PLx Pharma Inc (NASDAQ:PLXP)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.92 and traded as high as $5.30. PLx Pharma shares last traded at $5.18, with a volume of 4,038 shares traded.

Several research firms have commented on PLXP. Zacks Investment Research downgraded shares of PLx Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. ValuEngine downgraded shares of PLx Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, February 4th.

The business’s 50 day moving average is $4.93 and its 200 day moving average is $5.07. The stock has a market cap of $47.50 million, a price-to-earnings ratio of -1.53 and a beta of 5.12.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of PLx Pharma by 150.1% during the second quarter. BlackRock Inc. now owns 9,897 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 5,939 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of PLx Pharma by 29.2% during the second quarter. Vanguard Group Inc. now owns 145,649 shares of the biotechnology company’s stock worth $1,049,000 after purchasing an additional 32,874 shares in the last quarter. Heritage Way Advisors LLC acquired a new position in shares of PLx Pharma during the third quarter worth $153,000. Finally, University of Texas Texas AM Investment Managment Co. acquired a new position in shares of PLx Pharma during the fourth quarter worth $274,000. Hedge funds and other institutional investors own 22.17% of the company’s stock.

PLx Pharma Company Profile (NASDAQ:PLXP)

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Featured Article: What is a back-end load?

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.